Skip to content

Weekday Japan business intelligence for finance professionals.

Join the list
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Renascience

レナサイエンス

4889 · TSE · Pharmaceutical · 1 article

Financials Company only

Revenue¥68.6m−48.3% year on yearCompany only · FY3/26

Ordinary profit−¥300mCompany only · FY3/26

Performance over time

Revenue
¥139mFY3/22
¥101mFY3/23
¥194mFY3/24
¥133mFY3/25
¥68.6mFY3/26
Ordinary profit
−¥242mFY3/22
−¥334mFY3/23
−¥252mFY3/24
−¥179mFY3/25
−¥300mFY3/26
Op. cash flow
−¥230mFY3/22
−¥285mFY3/23
−¥231mFY3/24
−¥176mFY3/25
−¥291mFY3/26

People & pay

Employees3 peopleFY3/26

Average salary¥4.98mFY3/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitEPSTotal assetsNet assetsOp. cash flow
FY3/26¥68.6m−48.3% year on year−¥300m−¥23.39¥3.50bn¥3.32bn−¥291m
FY3/25¥132.7m−31.7% year on year−¥179m¥8.92¥1.87bn¥1.72bn−¥176m
FY3/24¥194.2m+93.1% year on year−¥252m−¥20.32¥2.09bn¥1.61bn−¥231m
FY3/23¥100.5m−27.8% year on year−¥334m−¥26.42¥2.27bn¥1.87bn−¥285m
FY3/22¥139.3m−¥242m−¥22.33¥2.44bn¥2.20bn−¥230m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100YGXR · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4889

  1. Renascience's Skin-Cancer Drug RS5614 Gets Japan's Orphan Status, Not Yet Approval

    Japan's health ministry designated Renascience's RS5614 an orphan drug for the rare skin cancer cutaneous angiosarcoma, extending exclusivity and adding a pricing premium, while the company discusses a Phase 3 trial with Japan's PMDA aimed at regulatory approval.

Fund positioning

Current holdings disclosed by tracked funds.

1 fund · data through

Held by 1 tracked fund; largest weight 0.12%. Holdings as of 6 Nov 2026.

Fund positioning
FundNAV weight
TSE Growth 250 ETF0.12%